期刊
ANNALS OF GASTROENTEROLOGICAL SURGERY
卷 4, 期 2, 页码 100-108出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/ags3.12311
关键词
neoadjuvant chemotherapy; neoadjuvant therapy; pancreatic adenocarcinoma; resectable pancreatic cancer
资金
- Takeda Pharmaceutical Company
Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy. Despite the many reports of the efficacy of neoadjuvant therapy, most of them were not comparative. Recently Prep-02/JSAP05 study clearly demonstrated the significant survival benefit of neoadjuvant chemotherapy over upfront surgery for pancreatic adenocarcinoma that is planned for resection. These findings opened a new chapter of neoadjuvant therapy. Ongoing trials are expected to confirm the evidence. This review summarizes the past, present, and future perspectives of neoadjuvant therapy and its optimization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据